C1-inhibitor: An anti-inflammatory reagent with therapeutic potential

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 7, 2001, Pages 1073-1083

  Kirschfink, M ^a   Mollnes, T E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

C1 inhibitor; Complement; Inflammation; Review; Therapy

Indexed keywords

ANTIINFLAMMATORY AGENT; COMPLEMENT COMPONENT C1S INHIBITOR;

ALZHEIMER DISEASE; ANGIONEUROTIC EDEMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; BURN; CAPILLARY LEAK SYNDROME; CLINICAL TRIAL; COMPLEMENT SYSTEM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; HEART INFARCTION; HUMAN; INFECTION; INFLAMMATORY DISEASE; NONHUMAN; RAT; REVIEW; SEPTICEMIA; SIDE EFFECT; STROKE; SURGICAL INJURY; TRANSPLANTATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COMPLEMENT C1 INACTIVATOR PROTEINS; HUMANS; MODELS, CHEMICAL; MYOCARDIAL ISCHEMIA; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; WOUNDS AND INJURIES;

EID: 0034930015     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.7.1073     Document Type: Review

References (138)

1. Molecular organization and function of the complement system
2. The mannan-binding-lectin pathway of the innate immune response
3. Control of the complement system
4. Control of the classical and the MBL pathway of complement activation
5. Complement in the pathophysiology and diagnosis of human diseases
6. Controlling the complement system in inflammation
7. Targeting complement in therapy
8. Therapeutic inhibition of the complement system
9. Therapeutic interventions in the complement system
10. Influence of C1-inhibitor on inflammation, edema and shock
11. C1 inhibitor in anti-inflammatory therapy: From animal experiment to clinical application
12. Therapeutic inhibition of the complement system
13. C1-Esterase inhibitor: An anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema
14. The regulation of C1 activation and its role in disease
15. Molecular cloning of human C1 inhibitor: Sequence homologies with alpha 1-antitrypsin and other members of the serpins superfamily
16. C1-inhibitor: Structure/function and biologic role
17. Human C1 inhibitor: Primary structure, cDNA cloning, and chromosomal localization
18. Three-dimensional structure and molecular modelling of C1-inhibitor
19. Interaction of 1251-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma
20. Proteolytic activities of two types of mannose-binding lectin-associated serine protease
21. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator
22. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'lr subcomponent of the first component of complement by serum C'1 esterase inhibitor
23. C1 inhibitor: The predominant inhibitor of plasma kallikrein
24. Inactivation of kallikrein in human plasma
25. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma
26. Inhibition of activation of human T lymphocytes by the complement C1 esterase inhibitor
27. C1-esterase inhibitor blocks T lymphocyte proliferation and cytotoxic T lymphocyte in vitro
28. The presence of a C1-inhibitor-like molecule (C1-INHL) on human sperm: Its involvement in sperm motility
29. Complement component 1 inhibitor (C1-INH) like protein on murine spermatozoa: Anti-C1-INH inhibits in vitro fertilization
30. Mechanism of serpin action: Evidence that C1 inhibitor functions as a suicide substrate
31. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes
32. Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase
33. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema
34. Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases
35. Half-life of C1INH in hereditary angioneurotic oedema (HAE)
36. C1-inhibitor concentrate for treatment of hereditary angioedema
37. Replacement therapy in hereditary angioedema: Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor
38. Quantification of plasma factor XIIa-C1-inhibitor and kallikrein-C1-inhibitor complexes in sepsis
39. Proteolytic inactivation of plasma C1-inhibitor in sepsis
40. Heparin binding and augmentation of C1 inhibitor activity
41. Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins
42. Heparin is not just an anticoagulant anymore: Six and one-half decades of studies on the ability of heparin to regulate complement activity
43. Potentiation of C1 inhibitor plus heparin in prevention of complement-mediated activation of endothelial cells in a model of xenograft hyperacute rejection
44. Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models
45. C1 inhibitor and hereditary angioneurotic edema
46. Inherited and acquired deficiencies of C1 esterase inhibitor in humans
47. Hereditary and acquired C1-inhibitor deficiency-biological and clinical characteristics in 235 patients
48. Hereditary angioedema
49. Acquired angioedema with lymphoproliferative disorder: Association of C1 inhibitor deficiency with cellular abnormality
50. Autoantibody-mediated acquired deficiency of C1 inhibitor
51. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency
52. Prospective virus safety follow-up after therapy with a pasteurized C1-inhibitor concentrate
53. Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate
54. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate
55. Biochemical investigations after burning injury: Complement system, protease-antiprotease balance and acute-phase reactants
56. Postburn edema and related changes in interleukin-2, leukocytes, platelet activation, endothelin-1, and C1 esterase inhibitor
57. Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome
58. Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome
59. Activity of C1 esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation
60. Effects of high-dose intraperitoneal aprotinin treatment on complement activation and acute phase response in acute severe pancreatitis
61. Plasma levels of prekallikrein, alpha-2-macroglobulin and C1-esterase inhibitor in patients with urticarial reaction to contrast media
62. Global and extended coagulation monitoring during extracorporeal lung assist with heparin-coated systems in ARDS patients
63. Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects
64. Levels of the terminal complement complex, C3a-desArg and C1-inhibitor in adult patients with capillary leak syndrome following bone marrow transplantation
65. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2
66. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2
67. A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2
68. C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation
69. Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: Treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate
70. The complement regulators C1 inhibitor and soluble complement receptor 1 attenuate acute lung injury in rabbits
71. Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction
72. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates
73. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis
74. The role of plasma proteases in septic shock
75. C1-esterase inhibitor in early septicemia
76. On the value of giving a combination of drugs for the treatment of endotoxaemia in pigs
77. Endotoxin-induced pulmonary dysfunction is prevented by C1- esterase inhibitor
78. The influence of C1-esterase inhibitor substitution on coagulation and cardiorespiratory parameters in an endotoxin-induced rabbit model of hypercoagulability
79. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock
80. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin
81. Effect of C1-inhibitor in a rat model of necrotizing enterocolitis
82. C1-esterase inhibitor and its effects on endotoxin-induced leukocyte adherence and plasma extravasation in postcapillary venules
83. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement
84. C1-esterase inhibitor substitution in sepsis
85. C1-inhibitor concentrate for sepsis-related capillary leak syndrome
86. The effect of C1-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Report of seven patients
87. Septic shock after liver transplantation for Caroli's disease: Clinical improvement after treatment with C1-esterase inhibitor
88. Antiprotease capacity in acute pancreatitis
89. Activation of proteases in cerulein-induced pancreatitis
90. Effects on peritoneal proteolysis and hemodynamics of prophylactic infusion with C1 inhibitor in experimental acute pancreatitis
91. Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis
92. Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy
93. Effects of C1-esterase inhibitor in three models of acute pancreatitis
94. Adjuvant treatment of severe acute pancreatitis with C1 esterase inhibitor concentrate after haematopoietic stem cell transplantation
95. The complement system in trauma-related and ischemic tissue damage: A brief review
96. Beneficial effects of C1 esterase inhibitor in murine traumatic shock
97. Inhibition of the hypotensive effect of plasma protein solutions by C1 esterase inhibitor
98. Postoperative multiple organ dysfunction syndrome associated with gut mucosal hypoperfusion, increased neutrophil degranulation and C1-esterase inhibitor depletion
99. Capillary leak syndrome after open heart surgery for congenital heart defects: Therapy with C1-inhibitor
100. Arzneimittelkommission Der Deutschen Ärzteschaft: Schwerwiegende Thrombenbildung nach Berinert S
101. Heparin and modified heparin inhibit complement activation in vivo
102. Potentiation of C1 inhibitor by glycosaminoglycans: Dextran sulfate species are effective inhibitors of in vitro complement activation in plasma
103. Extracorporeal Circulation - In vivo and in vitro analysis of complement activation by heparin-bonded surfaces
104. Biocompatibility: Complement as mediator of tissue damage and as indicator of incompatibility
105. C1 inhibitor prevents capillary leakage after thermal trauma
106. C1-esterase inhibitor (C1-INH) as adjuvant therapy for septic shock following severe thermal trauma
107. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion
108. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion
109. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury
110. Activation of clotting factors XI and IX in patients with acute myocardial infarction
111. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA
112. Complement inhibition and myocardial protection in patients with acute myocardial infarction
113. In vivo microscopy reveals that complement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver
114. C1-esterase inhibitor reduces infarct volume after cortical vein occlusion
115. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes
116. The role of complement in transplantation
117. C1-esterase inhibitor prevents early pulmonary dysfunction after lung transplantation in the dog
118. Improved right ventricular function after intracoronary administration of a C1 esterase inhibitor in a right heart transplantation model
119. C1-esterase-inhibitor levels in patients with and without reperfusion injury following lung transplantation (LTx)
120. C1-esterase inhibitor in graft failure after lung transplantation
121. Role of complement in xenotransplantation
122. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor
123. Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1. Analysis in a pig-to-human in vitro hyperacute xenograft rejection
124. C1-Inh and heparan sulfate can prevent discordant rejection
125. C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model
126. C1-inhibitor attenuates human serum induced E-selectin expression of pig aortic endothelial cells
127. A surface-bound form of human C1 esterase inhibitor improves xenograft rejection
128. Regulation of complement-mediated swine endothelial cell lysis by a surface-bound form of human C4b binding protein
129. Complement activation, its consequences, and blockade by gene transfer
130. Potential use of genetically modified pigs as organ donors for transplantation into humans
131. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide
132. Complement C1-inhibitor expression in Alzheimer's disease
133. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor
134. Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease
135. Recombinant C1-inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils
136. Expression of active human C1 inhibitor serpin domain in Escherichia coli